Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yang, Xiaobing
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis	Completed	2	140	RoW	Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group	Tianjin Hemay Pharmaceutical Co., Ltd	Rheumatoid Arthritis	06/23	06/23
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus	Recruiting	2	186	RoW	Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo	Beijing InnoCare Pharma Tech Co., Ltd.	Systemic Lupus Erythematosus, SLE	08/25	05/26